Imaging and CSF testing prior auth considerations — Therapy monitoring imaging steps

Brain MRI and CSF testing used in association with initiation and monitoring of aducanumab (Aduhelm) or lecanemab (Leqembi) have specific timing and documentation expectations. A brain MRI is required within one year prior to initiating Aduhelm or Leqembi to indicate AD, and additionally prior to specific dose milestones to evaluate for amyloid-related imaging abnormalities (ARIA): prior to the 5th, 7th, 9th, and 12th aducanumab dose and prior to the 5th, 7th, and 14th lecanemab dose. Lumbar puncture for CSF biomarkers (Aβ42, Aβ40 ratio, total tau, phosphorylated tau) may be medically necessary for assessment of MCI when AD is suspected but results and interpretation must be documented in the medical record. Providers should obtain and retain imaging and CSF reports in the member's chart to support medical necessity when submitting claims.

• MRI timing: within 12 months pre-initiation; before 5th, 7th, 9th, 12th Aduhelm doses; before 5th, 7th, 14th Leqembi doses
• CSF LP: indicated to confirm elevated p-tau and/or t-tau and reduced Aβ42 or low Aβ42/Aβ40 ratio for MCI when AD is suspected

Prior authorization — regulatory note

This Clinical Policy Bulletin is intended to assist in administering plan benefits and does not itself establish prior authorization requirements. Specific prior authorization and benefit determinations are governed by the member's plan documents and any program disclosures; providers must follow plan provisions and submit prior authorization requests where required by the member's contract.

• Clinical Policy Bulletins do not constitute offers of coverage
• Prior authorization requirements are determined by the member’s benefit plan

Investigational / reimbursement caution

Many emerging biomarker tests (blood-based assays, proprietary panels, skin biopsy assays, novel CSF analytes) remain investigational or of limited clinical validation and are not universally reimbursed. Use of such tests may require prior authorization in some plans and may be denied if clinical utility or FDA-cleared/approved status is lacking.

• Examples: MindX blood mRNA panel, NeuroDiagnostics Discern skin biopsy, Syn-One cutaneous alpha‑synuclein testing
• Testing availability and reimbursement vary; check payer-specific prior authorization rules

Investigational tests may need prior authorization

Investigational tests (proprietary or not yet validated assays) may trigger prior authorization reviews or medical necessity denials. When ordering such tests, providers should verify plan coverage and submit documentation demonstrating why testing is required for patient management if prior authorization is requested.

• Prior authorization may be requested for investigational blood or skin-based AD biomarker tests
• Submit clinical rationale and supporting records when prior auth is required

Not applicable in this document segment

No step therapy requirements are described in this document segment.

Regulatory status implication

There are currently no FDA-approved in‑vitro diagnostics (IVDs) universally accepted for early detection of AD; absence of FDA-cleared tests or guideline endorsement increases the risk of noncoverage for experimental assays.

• No FDA-approved IVDs for early detection of AD noted in this bulletin
• Lack of regulatory approval may lead to denial or no reimbursement

Investigational status and reimbursement risk

Testing for many novel biomarkers remains investigational and is not universally reimbursed by most insurers. Providers should be aware that clinical utility is not established for numerous blood analytes, skin biopsy biomarkers, and some CSF analytes; reimbursement may be denied absent convincing evidence and plan coverage.

• Examples of investigational/limited-evidence tests listed in the policy: plasma Aβ42, CSF VILIP‑1, various CSF synaptic biomarkers, blood neurodegenerative analytes, Syn‑One cutaneous alpha‑synuclein
• Testing may be limited to research settings or clinical trials

Established use limitations

Certain tests have limited or unestablished roles (for diagnosis, monitoring, or therapy response). For example, the NeuroDiagnostics skin biopsy AD biomarker assays have not been established for monitoring responses to therapies; Syn‑One cutaneous alpha‑synuclein testing lacks guideline endorsement for AD management.

• NeuroDiagnostics Discern: safety and effectiveness not established for monitoring therapy response
• Syn‑One and similar peripheral tests: not described in key UpToDate reviews; absence from guidelines may trigger coverage denial

Not applicable in this excerpt — no explicit prior authorization rules present

No explicit prior authorization rules are present in this excerpt for many individual tests; however, absence of payer-specific prior authorization language in the bulletin does not imply coverage. Providers must consult the member’s benefit plan and prior authorization resources.

Guideline/gold-standard absence may trigger denial

When tests lack guideline or gold-standard support (for example, Syn‑One cutaneous alpha‑synuclein testing or proprietary risk-score algorithms without independent validation), payers may deny coverage. Providers should document why such testing is clinically necessary and reference supporting evidence when available.

• Absence from AAN/UpToDate guidance or major clinical guidelines increases denial risk
• Provide literature or trial justification if requesting coverage for nonstandard tests

Clinical indication documentation

Document the clinical indication for testing: suspected AD or MCI, atypical presentation, early-onset (<50 years) considerations for genetic testing related to trial enrollment, or need for confirmation before initiating disease-modifying therapies (e.g., Aduhelm or Leqembi). For therapy-related imaging or CSF testing, document timing relative to initiation and dosing milestones.

• Indications to document: suspected AD, MCI with suspected AD, atypical presentation, early-onset dementia (<50 years) when considering genetic testing for APP/PSEN1/PSEN2 for trial enrollment
• Document relation to therapy initiation and monitoring (Aduhelm/Leqembi dosing schedule)

Clinical measurement notes

When reporting biomarker results, include measurement methods and thresholds where applicable (e.g., CSF VILIP‑1 ≥560 pg/mL associated with more rapid decline in one study) and note that biomarker ratios such as p‑tau/Aβ42 or t‑tau/Aβ42 often provide better diagnostic discrimination than single analytes.

• Report specific analyte values and any lab-specific cutoffs or ratios (p‑tau/Aβ42, t‑tau/Aβ42, Aβ42/Aβ40)
• Example: CSF VILIP‑1 ≥560 pg/mL associated with faster cognitive decline in early AD cohort

Reporting confounders for CSF biomarker interpretation

Reports interpreting CSF biomarker results should include potential confounders that affect diagnostic performance: patient age, disease duration, and degree of cognitive impairment. Studies recommend reporting these variables to aid interpretation.

• Key confounders: age, disease duration, global cognitive impairment (e.g., MMSE), and timing relative to symptom onset
• Note whether CSF and/or amyloid PET confirmation was available

Required clinical documentation for CSF biomarker use

Required clinical documentation when using CSF biomarkers: indication for testing, description of symptoms and cognitive testing results, imaging findings if available, laboratory method/assay used (including whether automated validated platforms were used), and how results will affect patient management. CSF biomarkers should support but not replace clinical assessment.

• Include symptom description, cognitive testing scores, and imaging findings
• Document assay platform (e.g., automated Elecsys) and lab performing the test
• State how results will change management (diagnosis confirmation, trial eligibility, therapy decision)

Specimen and report requirements

Vendor-proprietary tests require a prescription and submission of specific specimen types and processing instructions. For example, the MindX blood mRNA panel and NeuroDiagnostics Discern skin biopsy are prescription-only and have vendor-specific specimen requirements and turnaround processes; providers must follow manufacturer/laboratory instructions and include required clinical information on the order.

• MindX: whole blood RNA sequencing of 24 genes — prescription required
• NeuroDiagnostics Discern: 2–3 mm skin punch biopsy from bicep/forearm — specimen handling and culture grown per vendor instructions

Recommended documentation elements (research/clinical studies)

When ordering and documenting investigational or research-oriented biomarker testing, include the elements commonly reported in published studies: raw analyte concentrations, ratios (p‑tau/Aβ42, t‑tau/Aβ42, Aβ42/Aβ40), assay platform and validation status (e.g., Simoa, automated immunoassay), and comparison group details if relevant. Indicate whether results were corroborated by CSF or amyloid PET when available.

• Document analytes measured (GFAP, p‑tau181, p‑tau231, NfL, Aβ42, Aβ40, total tau) and assay used (eg, Simoa, Elecsys)
• Include group characteristics and reference ranges where reported

Document study limitations and lack of biomarker confirmation

Study reports frequently note limitations that affect clinical generalizability: cross-sectional design, small sample sizes, lack of amyloid PET or CSF confirmation in all participants, and limited ethnic diversity. Providers should acknowledge such limitations in justification for testing and when interpreting results.

• Common limitations: cross-sectional data, lack of confirmatory PET/CSF, small or homogeneous cohorts, differences in assay methods between studies
• Include these limitations when submitting rationale for testing

Provider responsibilities

Treating providers are responsible for following plan provisions, obtaining required authorizations, documenting medical necessity, and managing member care. Clinical Policy Bulletins are an administrative tool and do not replace provider judgment. Providers should ensure records support services billed and be prepared to supply documentation for prior authorization or appeals.

• Providers remain solely responsible for medical advice and treatment
• Follow plan prior authorization procedures and retain documentation to support claims

Genetic testing guidance

Genetic testing guidance: routine APOE genotyping and broad genetic testing are not recommended for routine evaluation of dementia. Genetic mutation testing for APP, PSEN1, or PSEN2 may be appropriate for individuals with MCI or mild AD dementia who are younger (for example, <50 years) and are being considered for enrollment in clinical trials of aducanumab or lecanemab; document age, clinical context, and trial consideration when ordering.

• AAN and UpToDate do not recommend routine APOE genotyping for AD diagnosis
• Consider APP/PSEN1/PSEN2 testing in early-onset cases being evaluated for clinical trial eligibility